"Aravindhan Veerapandiyan" / Publisher: right vision media - Searchworks@Jio Institute Digital Library Search Results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Your search keyword '"Aravindhan Veerapandiyan"' showing total 10 results

Start Over "Aravindhan Veerapandiyan" Publisher right vision media

10 results on '"Aravindhan Veerapandiyan"'

1. REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE(r) TRIAL OF RGX-202

Subjects: Dystrophin, Utrophin, General interest, News, opinion and commentary
Abstract: ROCKVILLE: REGENXBIO Inc. has issued the following news release: REGENXBIO Inc. (Nasdaq: RGNX) reported new, positive interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE(r) trial of RGX-202 [...]
Published: 2024

2. REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE(r) TRIAL

Subjects: General interest, News, opinion and commentary
Abstract: ROCKVILLE: REGENXBIO Inc. has issued the following news release: REGENXBIO Inc. (Nasdaq: RGNX) reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE(r) trial of RGX-202 in [...]
Published: 2024

3. REGENXBIO to Hosted Webcast Event to Discuss New Interim Clinical Data from the Phase I|II AFFINITY DUCHENNE(r) Trial

Subjects: Clinical trials, General interest, News, opinion and commentary
Abstract: ROCKVILLE: REGENXBIO Inc. (Nasdaq: RGNX) announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE(r) trial of RGX-202 for the [...]
Published: 2024

4. REGENXBIO Presents Interim Clinical Data from Phase I|II AFFINITY DUCHENNEtm Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

Subjects: Dystrophin, Societies, Clinical trials, Associations, institutions, etc., General interest, News, opinion and commentary
Abstract: ROCKVILLE, Md: REGENXBIO Inc. has issued the following news release: REGENXBIO Inc. (Nasdaq: RGNX) today announced additional interim safety data and initial efficacy data from the Phase I/II AFFINITY DUCHENNEtm [...]
Published: 2023

5. REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

Subjects: Societies, Associations, institutions, etc., General interest, News, opinion and commentary
Abstract: ROCKVILLE: REGENXBIO Inc has issued the following news release: REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in Charleston, [...]
Published: 2023

6. REGENXBIO Announces Phase I|II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

Subjects: Dystrophin, Duchenne muscular dystrophy -- Care and treatment, Gene therapy, Utrophin, Clinical trials, General interest, News, opinion and commentary
Abstract: ROCKVILLE: REGENXBIO Inc. has issued the following news release: REGENXBIO Inc. (Nasdaq: RGNX) today announced that the Phase I/II AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne muscular [...]
Published: 2023

7. Parent Project Muscular Dystrophy Announces First Patients Consented into Electronic Health Record (EHR) Study

Subjects: Medical research, Medicine, Experimental, Muscular dystrophy, Medical records, General interest, News, opinion and commentary
Abstract: WASHINGTON: Parent Project Muscular Dystrophy (PPMD) has issued the following news release: Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today [...]
Published: 2022

8. AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy

Subjects: Genetic disorders, Clinical trials, Myotonic dystrophy, General interest, News, opinion and commentary
Abstract: LONDON: AMO Pharma Limited has issued the following press release: AMO Pharma Limited ('AMO Pharma'), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no [...]
Published: 2021

9. Parent Project Muscular Dystrophy Receives $100,000 Award from Duchenne Research Fund to Address Neurobehavioral Issues in Duchenne

Subjects: Muscular dystrophy, General interest, News, opinion and commentary
Abstract: HACKENSACK: Parent Project Muscular Dystrophy (PPMD) has issued the following news release: Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today [...]
Published: 2021

10. AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02 in Treatment of Congenital Myotonic Dystrophy

Subjects: United States. Food and Drug Administration, Genetic disorders, Clinical trials, Myotonic dystrophy, General interest, News, opinion and commentary
Abstract: LONDON: AMO Pharma Limited has issued the following press release: AMO Pharma Limited ('AMO Pharma'), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with limited or [...]
Published: 2020

Catalog

Books, media, physical & digital resources

See catalog results